Abstract
OBJECTIVE:
To evaluate the management strategies available for the complications associated with bacillus Calmette–Guérin (BCG) immunotherapy in the treatment of bladder cancer.
DATA SOURCES:
Clinical literature accessed through MEDLINE (January 1983–January 1999). Key search terms included bacillus Calmette-Guérin, BCG, and bladder cancer.
DATA SYNTHESIS:
BCG vaccine is a live-attenuated strain of Mycobacterium bovis; therefore, the risk for complications exists. An evaluation of treatment regimens was conducted, and the management strategies are presented.
CONCLUSIONS:
The complications associated with BCG immunotherapy range from local reactions to potentially fatal systemic reactions requiring long-term therapy. Therefore, healthcare practitioners need to be aware of the current treatment regimens available.
Get full access to this article
View all access options for this article.